ANNX20261218C9
ANNX Dec 18 2026 9.00 Call (ANNX261218C00009000)
option OPRA

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington's disease and alzheimer's disease by targeting complement-mediated neurodegeneration (cmnd).